Drug Product

Guiding difficult to develop drug molecules from preclinical to clinical by resolving solubility, bioavailability, physical form and stability challenges

Aragen offers innovative, end-to-end solutions to accelerate clinical candidates from preclinical to clinical stages. Our scientific expertise spans formulation development, solid-state chemistry, material science, and analytics. We specialize in resolving complex challenges—including solubility, bioavailability, physical form, and stability—to enable successful drug product advancement.

Our formulation and analytical laboratories supported by multidisciplinary teams, ensure development of robust dosage forms while minimizing drug substance requirements. A dedicated technology transfer team ensures seamless scale-up and clinical manufacturing to support clinical trials and regulatory submissions.

Why Aragen?

Strong Scientific Expertise

• End-to-end formulation and analytical development support from discovery to CMC
• Deep expertise in pre-formulation, material science, and solid-state chemistry
• Integrated formulation and analytical characterization capabilities

Proven Technology Platforms

• Spray Dried Dispersions (SDDs/ASDs)
• Nanosuspensions
• Peptides and complex molecules
• Experience supporting biotech and pharma sponsors across formulation and analytical development programmes.

Dosage Forms Developed

• Oral Solids: DiB, DiC, Immediate Release (IR), Controlled Release (CR), SDDs
• Injectables: Solutions, suspensions, nanosized formulations, long-acting injectables (LAIs)
• Topicals and other non-oral dosage forms

Dedicated Infrastructure

• Suites for preclinical, solid-state/material science, and pre-formulation
• Clinical formulation, method development, validation & stability labs
• cGMP clinical drug product manufacturing facility (solid orals for Phase I–II)

Proven Track Record

• Pre-formulation and formulation development support to over 500+ NCEs
• Supported clinical development for over 50 drug products
• GMP clinical manufacturing and QP release for over 20 clinical batches within two years of operations during Fiscals 2026 and 2025
• Team of experienced scientists and subject matter experts (including PhDs)